세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 보고서(2025년)

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,222,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,993,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,765,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 5.6%의 연평균 성장률로 104억 8,000만 달러 규모에 이를 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 정밀 종양학 및 바이오마커 기반 치료의 채택 증가, 차세대 호르몬 치료 및 방사성 리간드 치료에 대한 수요 증가, 진행성 전립선암에 대한 임상 검사 파이프라인 확대, 표적 및 면역 종양학 약물 파이프라인의 성장, 맞춤형 의료 전략에 대한 수요 증가에 기인할 것으로 보입니다. 수요 증가에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 면역요법 병용요법 개발, 임상적 의사결정에 유전체 프로파일링 도입, 환자 모니터링에 디지털 헬스 툴 활용, 이중특이성 T세포 인게이저의 혁신, 종양 미세환경 조절제의 발전 등을 들 수 있습니다.

전립선암의 유병률 증가는 향후 몇 년 동안 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장의 성장을 촉진할 것으로 예상됩니다. 전립선암은 방광 아래쪽과 직장 앞에 위치한 남성의 작은 기관인 전립선에 발생하는 암의 일종입니다. 전립선암의 발병에는 고령화가 크게 기여하고 있습니다. 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료는 표준 호르몬 요법이 효과가 없는 진행성 전립선암을 치료하는 데 사용됩니다. 이러한 치료는 질병의 진행을 늦추고, 증상을 관리하고, 삶의 질을 개선함으로써 환자의 예후를 개선합니다. 예를 들어, 2024년 11월 영국 정부 기관인 National Health Service는 2022년 신규 전립선암 환자가 5만 4,732명으로 2021년 대비 1만 1,354명 증가했다고 보고했습니다. 따라서 전립선암 유병률의 증가는 CRPC/HRPCA 치료 시장의 성장을 촉진하고 있습니다.

거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료제 시장의 주요 기업들은 치료 효과와 환자 예후를 개선하기 위해 혁신적인 제품을 개발하고, 듀얼 액션 정제와 같은 약사 승인을 확보하는 데 주력하고 있습니다. 듀얼 액션 정제는 한 번의 투여로 두 가지 치료법을 결합하여 CRPC 치료에 관여하는 여러 경로를 동시에 표적으로 삼는 첨단 제제입니다. 예를 들어, 벨기에에 본사를 둔 제약사 얀센 파마슈티컬스는 2023년 8월 미국 식품의약국(FDA)으로부터 BRCA 유전자 변이가 있는 전이성 거세저항성 전립선암(mCRPC) 성인 환자를 위한 새로운 정제 '아퀴가'를 승인받았습니다. 아퀴가는 PARP 억제제(니라파립)와 CYP17 억제제(아비라테론 아세테이트)를 통합한 정밀 의약품으로, 특히 BRCA 유전자 변이 환자를 대상으로 합니다. 프레드니손과 병용 투여 시 표준 호르몬 요법 대비 방사선학적 무진행 생존기간(rPFS)을 유의하게 개선합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 성장률 분석
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 : 총 잠재 시장 규모(TAM)

제6장 시장 세분화

• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 치료 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 호르몬요법
• 화학요법
• 면역요법
• 표적요법
• 방사선 치료
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 주사제
• 정맥내
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 종양학 센터
• 외래 수술 센터
• 기타
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 호르몬요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 안드로겐 수용체(AR) 억제제
• 안드로겐 합성 억제제
• 황체 형성 호르몬 방출 호르몬(LHRH) 작용제/길항제
• 성선자극호르몬 방출 호르몬(GnRH) 작용제/길항제
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 화학요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 타키산
• 플래티넘 기반 약제
• 기타 화학요법
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 면역요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 면역관문억제제
• 암 백신
• 사이토카인 요법
• 양자 세포 치료
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 표적요법 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 폴리 ADP-리보오스 폴리메라아제(PARP) 억제제
• 포스포이노시타이드3 키나아제(PI3K)/단백질 키나아제 B(PI3K)/포유류 라파마이신 표적(mTOR) 억제제
• 티로신 키나아제 억제제(TKI)
• 데옥시리보핵산 손상 응답(DDR) 억제제
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 방사선 치료 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 외부 방사선 치료
• 근접 방사선 치료
• 방사성의약품

제7장 지역별·국가별 분석

• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 경쟁 구도
• 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장 : 기업 개요
  • Pfizer Inc.
  • Johnson And Johnson
  • Merck & Co. Inc.
  • Bayer AG
  • Novartis AG

제31장 기타 주요 기업과 혁신적 기업

• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Daiichi Sankyo Co. Ltd.
• Lantheus Holdings Inc.
• POINT Biopharma Global Inc.
• Clovis Oncology Inc.
• Arvinas Inc.
• Clarity Pharmaceuticals Ltd
• Modra Pharmaceuticals B.V.
• Oncternal Therapeutics Inc.
• Zenith Epigenetics Ltd.
• ESSA Pharma Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

• 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 2029년 : 새로운 기회를 제공하는 국가
• 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 2029년 : 새로운 기회를 제공하는 부문
• 거세저항성 전립선암(CRPC)/호르몬 저항성 전립선암(HRPCA) 치료 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Castration-resistant prostate cancer (CRPC), also known as hormone-refractory prostate cancer (HRPCA), therapeutics include drugs and treatments designed for CRPC-an advanced stage of prostate cancer that continues to advance despite reduced testosterone levels, typically following androgen deprivation therapy. These treatments are intended to address resistance mechanisms, enhance patient outcomes, and prolong survival.

The primary therapy types for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Hormonal therapy involves using hormones or hormone-blocking medications to inhibit or slow the growth of hormone-sensitive cancers. These treatments are delivered through oral, injectable, and intravenous methods and are utilized by various end users, such as hospitals, oncology centers, ambulatory surgical centers, and others.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market research report is one of a series of new reports from The Business Research Company that provides castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market statistics, including the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics industry's global market size, regional shares, competitors with the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market share, detailed castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. This castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the rising incidence of prostate cancer, increased use of androgen deprivation therapy (ADT) resulting in resistance, expanded availability of targeted therapy options, advancements in diagnostic imaging capabilities, and growing healthcare investments in oncology infrastructure.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The projected growth during the forecast period can be attributed to the increasing adoption of precision oncology and biomarker-driven therapies, rising demand for next-generation hormonal treatments and radioligand therapy, an expanding clinical trial pipeline for advanced prostate cancer, a growing pipeline of targeted and immuno-oncology agents, and a heightened demand for personalized medicine strategies. Key trends expected during this period include the development of combination immunotherapy regimens, the incorporation of genomic profiling into clinical decision-making, the use of digital health tools for patient monitoring, innovations in bispecific T-cell engagers, and advancements in tumor microenvironment modulators.

The increasing prevalence of prostate cancer is anticipated to drive the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is a form of cancer that originates in the prostate gland, a small organ in men located beneath the bladder and in front of the rectum. The growing prevalence of prostate cancer is largely attributed to the aging population, as the likelihood of developing the disease rises significantly with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are used to treat advanced stages of prostate cancer that no longer respond to standard hormone therapy. These treatments enhance patient outcomes by slowing disease progression, managing symptoms, and improving quality of life. For example, in November 2024, the National Health Service, a government agency in the UK, reported that new prostate cancer cases reached 54,732 in 2022, reflecting an increase of 11,354 cases compared to 2021. Hence, the rising prevalence of prostate cancer is fueling the growth of the CRPC or HRPCA therapeutics market.

Leading companies in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on the development of innovative products and securing regulatory approvals, such as dual-action tablets, to improve treatment effectiveness and patient outcomes. Dual-action tablets are advanced formulations that combine two therapeutic agents in a single dose to concurrently target multiple pathways involved in the treatment of CRPC. For example, in August 2023, Janssen Pharmaceuticals, a pharmaceutical company based in Belgium, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a new tablet designed for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically aimed at patients with BRCA mutations. When administered with prednisone, it significantly improves radiographic progression-free survival (rPFS) compared to standard hormonal therapies.

In June 2024, AstraZeneca plc, a pharmaceutical company based in the US, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to revolutionize cancer treatment and outcomes by shifting from conventional chemotherapy and radiotherapy to more precise next-generation radioconjugate therapies. Fusion Pharmaceuticals Inc., a biotech firm headquartered in Canada, is actively developing FPI-2265, a targeted alpha therapy intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Major players in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market consists of sales of enzalutamide, darolutamide, abiraterone, and cabazitaxel. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
• 2) By Route Of Administration: Oral; Injectable; Intravenous
• 3) By End User: Hospitals; Oncology Centers; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors; Androgen Synthesis Inhibitors; Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists; Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
• 2) By Chemotherapy: Taxanes; Platinum-Based Agents; Other Chemotherapies
• 3) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine Therapy; Adoptive Cell Therapy
• 4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors; Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors; Tyrosine Kinase Inhibitors (TKIs); Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
• 5) By Radiation Therapy: External Beam Radiation Therapy; Brachytherapy; Radiopharmaceuticals
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Merck & Co. Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Characteristics

3. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Trends And Strategies

4. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Rate Analysis
• 5.4. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Total Addressable Market (TAM)

6. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmentation

• 6.1. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• 6.2. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intravenous
• 6.3. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Centers
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Androgen Receptor (AR) Inhibitors
• Androgen Synthesis Inhibitors
• Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists
• Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
• 6.5. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Taxanes
• Platinum-Based Agents
• Other Chemotherapies
• 6.6. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Cytokine Therapy
• Adoptive Cell Therapy
• 6.7. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Poly ADP-Ribose Polymerase (PARP) Inhibitors
• Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors
• Tyrosine Kinase Inhibitors (TKIs)
• Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
• 6.8. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Brachytherapy
• Radiopharmaceuticals

7. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Regional And Country Analysis

• 7.1. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 8.1. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 9.1. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 9.2. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 10.1. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 11.1. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 11.2. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 12.1. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 13.1. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 14.1. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 14.2. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 15.1. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 15.2. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 16.1. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 17.1. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 18.1. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 19.1. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 20.1. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 21.1. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 21.2. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 22.1. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 23.1. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 23.2. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 24.1. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 24.2. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 25.1. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 25.2. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 26.1. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 26.2. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 27.1. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 28.1. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 28.2. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

• 29.1. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
• 29.2. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Landscape
• 30.2. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Astellas Pharma Inc.
• 31.6. Daiichi Sankyo Co. Ltd.
• 31.7. Lantheus Holdings Inc.
• 31.8. POINT Biopharma Global Inc.
• 31.9. Clovis Oncology Inc.
• 31.10. Arvinas Inc.
• 31.11. Clarity Pharmaceuticals Ltd
• 31.12. Modra Pharmaceuticals B.V.
• 31.13. Oncternal Therapeutics Inc.
• 31.14. Zenith Epigenetics Ltd.
• 31.15. ESSA Pharma Inc.

32. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

34. Recent Developments In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

35. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료